Azaribine

Summary

Azaribine (CHEMBL515914) is an approved small-molecule prodrug.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 371.3 Da · C14H17N3O9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL515914
Name	Azaribine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	16574
ChEBI	CHEBI:88272
Molecular formula	C14H17N3O9
Molecular weight	371.3
InChIKey	QQOBRRFOVWGIMD-OJAKKHQRSA-N

SMILES: CC(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C(=O)NC(=O)C=N2)OC(=O)C)OC(=O)C

IUPAC name: [(2R,3R,4R,5R)-3,4-diacetyloxy-5-(3,5-dioxo-1,2,4-triazin-2-yl)oxolan-2-yl]methyl acetate

ChEBI definition: A N-glycosyl-1,2,4-triazine that is 6-azauridine acetylated at positions 2’, 3’ and 5’ on the sugar ring. It is a prodrug for 6-azauridine and is used for treatment of psoriasis.

Pharmacological roles (ChEBI): antipsoriatic, prodrug.

Also known as: Azaribina, Azaribine, CB 304, CB-304, NSC-67239, Triazure, SID29215005, SID855722, AZARIBINE, SID144204429, SID170466075, AZARIBIN

Patent coverage: 719 distinct patent families (3,100 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,099 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Survival motor neuron protein, Prelamin-A/C, Thyroid hormone receptor beta, Beta-lactamase, Hypoxia-inducible factor 1-alpha.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	6.25	Potency	562.3	nM	CHEMBL_ACT_3652368
HIF1A	5.6	Potency	2512	nM	CHEMBL_ACT_4126784
HIF1A	5.6	Potency	2512	nM	CHEMBL_ACT_4520195
SMN1	5	Potency	10000	nM	CHEMBL_ACT_3880379

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).